trending Market Intelligence /marketintelligence/en/news-insights/trending/TuqvKu9cDoET4IGInjOkhg2 content esgSubNav
In This List

Alexion CFO to step down after 3rd quarter

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Alexion CFO to step down after 3rd quarter

Alexion Pharmaceuticals Inc. Executive Vice President and CFO Paul Clancy will step down from the role after filing results for the third quarter, which closes at the end of September.

Chief Strategy and Business Officer Aradhana Sarin will step in as the new CFO while Clancy will serve as senior adviser through half of 2020.

"Over the last two years, [Paul] has played an invaluable role in our efforts to rebuild Alexion, refocus our corporate strategy and position the company for its next chapter," Alexion CEO Ludwig Hantson said in a Sept. 17 release.

Sarin has worked for Alexion, a Boston company developing treatments for rare diseases, since late 2017, and she oversaw nine business development deals in that time.